Navigation Links
Endo Pharmaceuticals Provides Regulatory Update on New Formulation of OPANA® ER Designed to be Crush-Resistant
Date:1/7/2011

ectual property assets; market acceptance of our future products; government regulation of the pharmaceutical industry; our dependence on a small number of products; our dependence on outside manufacturers for the manufacture of most of our products; our dependence on third parties to supply raw materials and to provide services for certain core aspects of our business; new regulatory action or lawsuits relating to our use of narcotics in most of our core products; our exposure to product liability claims and product recalls and the possibility that we may not be able to adequately insure ourselves; our ability to protect our proprietary technology; the successful efforts of manufacturers of branded pharmaceuticals to use litigation and legislative and regulatory efforts to limit the use of generics and certain other products; our ability to successfully implement our acquisition and in-licensing strategy; regulatory or other limits on the availability of controlled substances that constitute the active ingredients of some of our products and products in development; the availability of third-party reimbursement for our products; the outcome of any pending or future litigation or claims by third parties or the government, and the performance of indemnitors with respect to claims for which we have the right to be indemnified; our dependence on sales to a limited number of large pharmacy chains and wholesale drug distributors for a large portion of our total revenues; significant litigation expenses to defend or assert patent infringement claims; any interruption or failure by our suppliers, distributors and collaboration partners to meet their obligations pursuant to various agreements with us; a determination by a regulatory agency that we are engaging or have engaged in inappropriate sales or marketing activities, including promoting the "off-label" use of our products; existing suppliers become unavailable or lose their regulatory status as an approved source, cau
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Arbor Pharmaceuticals, LLC. ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - ... of the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and ... on the current therapeutic developmental pipeline of Arbor ... stages, therapeutics assessment by drug target, mechanism of ...
(Date:9/30/2014)... DENVER , Sept. 30, 2014  According ... "the world of cancer clinical trials is going ... clinical trials and the work of the current ... these types of ,next generation, clinical trials, which ... tomorrow."  The company has been ...
(Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar Lipid Effects ... ... Population, SAN FRANCISCO, June 7 ... type 2 diabetes,that were enrolled in a Phase III study showed ...
... the ADA,s Annual Scientific Sessions, SAN FRANCISCO, ... of the dose-finding study for its new,injectable diabetes ... American Diabetes Association,s (ADA) 68th Annual Scientific Sessions,meeting ... that AVE0010 was well tolerated and significantly,improved glycemic ...
Cached Medicine Technology:Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 2Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 3Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 4New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 2New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 3New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 4
(Date:10/1/2014)... Long-acting insulin is safer and more effective than ... according to new research published in the ... and twice-daily doses of both long- and intermediate-acting ... , "In patients with Type 1 diabetes, we ... insulin when it came to controlling blood sugar, ...
(Date:10/1/2014)... holiday gift ideas? Éminence Organic Skin Care, the leader in ... season. Starting October 1st 2014, new spa gift sets are ... from two luxury skin care gift sets made from the ... to deliver whole body beauty. , The luxurious Body ... formulated to suit all skin types and will tick all ...
(Date:10/1/2014)... To help raise awareness about women’s health, leading Detroit ... several tips for women looking to live a healthier and ... should start each day with meditation, prayer and breathing exercises. ... yourself for the rest of the day and prevent the ... and fitness tips include:, -Drink half your weight in ounces ...
(Date:9/30/2014)... proactive about potential disease outbreaks like Ebola and establish ... Editorial in the October issue of Australian and ... from Monash University and Heath Kelly from the Australian ... , "Australia would do well to heed the lessons ... a consistent and outward looking response," the authors said. ...
(Date:9/30/2014)... conceived either less than one year or more than five ... increased risk for autism, a new study suggests. However, ... that the research can,t prove that birth spacing has any ... that parents understand that the odds for autism are still ... apart," said outside expert Dr. Andrew Adesman. He is chief ...
Breaking Medicine News(10 mins):Health News:Long-acting insulin is safer, more effective for patients with Type 1 diabetes 2Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 2Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 3Health News:In Recognition of National Women’s Health and Fitness Day, Cutler Integrative Medicine Details Tips for Living a Healthier and Happier Life 2Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2
... food to infants less than six months old is not ... allergies later and new moms should rather breastfeed them exclusively, ... avoided for the first six months, and certain items like ... until even later, according to the American College of Allergy, ...
... Consuming naturally occurring compounds in cocoa could improve ... also help blood flow// in menopausal women with ... and gives us new insights into how cocoa ... ways not previously known,' said Harold Schmitz, PhD, ...
... embryo formation has been discovered in malignant melanoma cells ... Scientist discovered this protein called Nodal by injecting malignant ... were able to induce abnormal embryonic skull and backbone ... published in online issue of the journal, Nature Medicine. ...
... the researchers at the University of Florida, Gainesville, mice based ... treat hereditary diseases of the heart.// , This ... with muscular dystrophy that damages the heart. The findings, published ... the way for studies in humans that could begin as ...
... Health service helpline NHS 24 has been criticized severely because a ... old lady.// ,Retired nurse Mary Smith, 87 had an ... helpline twice but the nurse curtly replied that she could not ... for a GP to attend to her. Then when the GP ...
... Hyderabad-based Aurobindo Pharma Ltd today said it has ... fixed drug combination product used for anti-HIV treatment. ... contains Lamivudine 150mg+2idovudine300mg tablets co-packaged with Abacavir 300mg ... ,This combination pack enhances convenience, is cost-effective ...
Cached Medicine News:Health News:Protein Involved In Embryo Formation Found In Malignant Cells 2Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 2Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 3Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 4
DNA/RNA preparation in 8-multi channels...
... units with hydrophobic PTFE membranes,Millex filter ... ideal for the sterilizing filtration of ... and for sterilizing or clarifying organic ... filter units are available with different ...
... Bottled Water, The Simplicity personal water system ... currently use bottled water. In addition to ... store bottled water, your laboratory applications may ... be absorbed from containers and cause water ...
... of Type I ultrapure water, , Ultrapure ... System is designed to provide the "final ... by reverse osmosis, distillation or deionization. Super-Q ... which exceeds Type I ASTM/CAP/NCCLS specifications.,The Super-Q ...
Medicine Products: